Overactive Bladder-Pipeline Review, H1 2017

Overactive Bladder-Pipeline Review, H1 2017


  • Products Id :- GMDHC9244IDB
  • |
  • Pages: 114
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Overactive Bladder-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder-Pipeline Review, H1 2017, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 7, 5, 5, 2, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overactive Bladder-Overview

Overactive Bladder-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Overactive Bladder-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Overactive Bladder-Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Allergan Plc

Asahi Kasei Pharma Corp

Astellas Pharma Inc

Dompe Farmaceutici SpA

Dong-A ST Co., Ltd.

FemmePharma Global Healthcare Inc

Hanmi Pharmaceuticals Co Ltd

Hydra Biosciences Inc

Ion Channel Innovations LLC

Ipsen SA

Jeil Pharmaceutical Co Ltd

Juniper Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Kyorin Pharmaceutical Co Ltd

Lipella Pharmaceuticals Inc

Merck & Co Inc

Mezzion Pharma Co Ltd

Ono Pharmaceutical Co Ltd

Recordati SpA

Roivant Sciences Ltd

Sanofi

Seoul Pharma Co Ltd

Taris Biomedical LLC

TheraVida Inc

Toray Industries Inc

XuanZhu Pharma Co Ltd

Overactive Bladder-Drug Profiles

(mirabegron + solifenacin succinate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(solifenacin succinate + tamsulosin hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abobotulinumtoxinA-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71441-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AK-14-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DA-8010-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DFL-23448-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fadanafil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HC-067047-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIP-1503-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPR-2579-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirabegron ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-8577-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxybutynin chloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Antagonize PACAP Receptor for Pelvic Pain Syndrome and Overactive Bladder-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pVAX-hSlo-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REC-0438-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RVT-901-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-244181-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV1 for Overactive Bladder-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize EP1 Receptor for Overactive Bladder-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize PTGER1 for Overactive Bladder-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solabegron hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solabegron hydrochloride MR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solifenacin succinate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solifenacin succinate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPO-1406-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THVD-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trospium chloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udenafil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vibegron-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Overactive Bladder-Dormant Projects

Overactive Bladder-Discontinued Products

Overactive Bladder-Product Development Milestones

Featured News & Press Releases

Oct 27, 2016: Velicept Therapeutics Names Clarence Young, M.D., Chief Medical Officer

Oct 07, 2016: Astellas Filed Lawsuit against Patent Infringement of Myrbetriq in the United States

Oct 05, 2016: Velicept Therapeutics Announces FDA Acceptance of IND Application of Novel, Once-Daily Formulation of Solabegron for the Treatment of Overactive Bladder

Sep 27, 2016: Allergan to Present New Data at the American Urogynecologic Society Annual Meeting in Denver

May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego

Mar 21, 2016: Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women

Jan 11, 2016: Juniper Pharmaceuticals Submits Pre-IND Meeting Request for its First Intra-vaginal Ring Product

Oct 15, 2015: Allergan Announces New Long-Term OnabotulinumtoxinA Treatment Study Results at the American Urogynecologic Society Meeting

Jun 15, 2015: NeXeption Forms New Company Velicept Therapeutics Intends to Merge with AltheRx Pharmaceuticals to Advance Solabegron for the Treatment of Overactive Bladder

May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial

May 05, 2015: Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting

Dec 08, 2014: Lipella's Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial

Apr 08, 2014: Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder

Oct 17, 2013: AltheRx Pharmaceuticals is Granted U.S. Patent for Use of Solabegron in Combination with Antimuscarinics for the Treatment of Overactive Bladder

Sep 11, 2013: Allergan's BOTOX Receives Authorisation for the Treatment of Overactive Bladder in the UK

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Overactive Bladder, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Overactive Bladder, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Overactive Bladder-Pipeline by Addex Therapeutics Ltd, H1 2017

Overactive Bladder-Pipeline by Allergan Plc, H1 2017

Overactive Bladder-Pipeline by Asahi Kasei Pharma Corp, H1 2017

Overactive Bladder-Pipeline by Astellas Pharma Inc, H1 2017

Overactive Bladder-Pipeline by Dompe Farmaceutici SpA, H1 2017

Overactive Bladder-Pipeline by Dong-A ST Co., Ltd., H1 2017

Overactive Bladder-Pipeline by FemmePharma Global Healthcare Inc, H1 2017

Overactive Bladder-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Overactive Bladder-Pipeline by Hydra Biosciences Inc, H1 2017

Overactive Bladder-Pipeline by Ion Channel Innovations LLC, H1 2017

Overactive Bladder-Pipeline by Ipsen SA, H1 2017

Overactive Bladder-Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Overactive Bladder-Pipeline by Juniper Pharmaceuticals Inc, H1 2017

Overactive Bladder-Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017

Overactive Bladder-Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Overactive Bladder-Pipeline by Lipella Pharmaceuticals Inc, H1 2017

Overactive Bladder-Pipeline by Merck & Co Inc, H1 2017

Overactive Bladder-Pipeline by Mezzion Pharma Co Ltd, H1 2017

Overactive Bladder-Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Overactive Bladder-Pipeline by Recordati SpA, H1 2017

Overactive Bladder-Pipeline by Roivant Sciences Ltd, H1 2017

Overactive Bladder-Pipeline by Sanofi, H1 2017

Overactive Bladder-Pipeline by Seoul Pharma Co Ltd, H1 2017

Overactive Bladder-Pipeline by Taris Biomedical LLC, H1 2017

Overactive Bladder-Pipeline by TheraVida Inc, H1 2017

Overactive Bladder-Pipeline by Toray Industries Inc, H1 2017

Overactive Bladder-Pipeline by XuanZhu Pharma Co Ltd, H1 2017

Overactive Bladder-Dormant Projects, H1 2017

Overactive Bladder-Dormant Projects, H1 2017 (Contd..1), H1 2017

Overactive Bladder-Dormant Projects, H1 2017 (Contd..2), H1 2017

Overactive Bladder-Dormant Projects, H1 2017 (Contd..3), H1 2017

Overactive Bladder-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Addex Therapeutics Ltd, Allergan Plc, Asahi Kasei Pharma Corp, Astellas Pharma Inc, Dompe Farmaceutici SpA, Dong-A ST Co., Ltd., FemmePharma Global Healthcare Inc, Hanmi Pharmaceuticals Co Ltd, Hydra Biosciences Inc, Ion Channel Innovations LLC, Ipsen SA, Jeil Pharmaceutical Co Ltd, Juniper Pharmaceuticals Inc, Kissei Pharmaceutical Co Ltd, Kyorin Pharmaceutical Co Ltd, Lipella Pharmaceuticals Inc, Merck & Co Inc, Mezzion Pharma Co Ltd, Ono Pharmaceutical Co Ltd, Recordati SpA, Roivant Sciences Ltd, Sanofi, Seoul Pharma Co Ltd, Taris Biomedical LLC, TheraVida Inc, Toray Industries Inc, XuanZhu Pharma Co Ltd

select a license

Single User License
USD 2000 INR 129520
Site License
USD 4000 INR 259040
Corporate User License
USD 6000 INR 388560

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com